MedTrace Logo

Study of a Bone Assessment Technique, Bone Mineral Analyser, Concerning the Prediction of Improvement in Bone Status After an Infusion of Zoledronic Acid in Osteoporotic Women

NCT04253340 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2026-02-10

No results posted yet for this study

Summary

* Collection of epidemiological data
* Biological assessment as part of routine care.
* Measurement of the Hurst coefficient at D0
* Measurement of bone density and TBS on D0
* Zoledronic acid infusion the month following inclusion
* phone call at 1 month (observance of zoledronic acid)
* Measurement of bone density, calculation of the Hurst coefficient at M12

Conditions

Interventions

DIAGNOSTIC_TEST

Bone mineral analyser

high resolution digital radiology (200 µm): D0 + M12 Trabecular Bone Score:D0 + M12 DXA scan:D0 + M12

Sponsors & Collaborators

  • University Hospital, Rouen

    lead OTHER

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-01
Primary Completion
2023-03-01
Completion
2023-03-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04253340 on ClinicalTrials.gov